Table 1.
Basic characteristics of all included studies.
| Author | Year | Country | Tumor stage | Sample size (male/female) | Median age (year) | Smoking rate (%) | Genotyping method | SNPs | Clinical outcomes | NOS |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun | 2009 | China | IV | 82 (53/29) | 59 | NR | DNA microarray | rs25487, rs1799782 | ORR | 6 |
| Yao | 2009 | China | IIIB-IV | 108 (71/38) | 61 | NR | PCR-RFLP | rs25487 | ORR, OS | 6 |
| Yuan | 2010 | China | III-IV | 199 (129/70) | 56 | 59.3 | PCR-RFLP | rs25487, rs1799782 | OS, PFS | 7 |
| Shiraishi | 2010 | Japan | III-IV | 201 (136/65) | 57.2 | 63.2 | TaqMan | rs25487 | ORR | 6 |
| Li | 2011 | China | III-IV | 89 (64/25) | 59.1 | NR | PCR-RFLP | rs25487 | ORR | 7 |
| Zhou | 2011 | China | IV | 111 (67/44) | 57 | NR | Direct sequencing | rs25487 | ORR | 7 |
| Liao | 2012 | China | IIIB-IV | 62 (35/27) | 57 | NR | SNPstream | rs25487 | ORR, OS | 6 |
| Ke | 2012 | China | I-IV | 460 (334/126) | 59.5 | 67.4 | PCR-CTTP | rs25487, rs1799782 | OS | 6 |
| Zhao | 2013 | China | IIIB-IV | 147 (92/55) | 60 | 45.9 | TaqMan | rs25487, rs1799782 | ORR, OS, PFS | 7 |
| Lee | 2013 | South Korea | III-IV | 382 (311/71) | NR | 83.2 | MALDI-TOF | rs25487 | ORR, OS | 6 |
| Zhang | 2014 | China | III-IV | 375 (249/126) | 60.9 | NR | MALDI-TOF | rs25487, rs1799782 | ORR, OS, PFS | 6 |
| Peng | 2014 | China | III-IV | 235 (180/55) | 58 | 61.3 | PCR-CTTP | rs25487 | ORR | 6 |
| Liu | 2014 | China | I-IV | 378 (297/81) | 62.4 | 56.1 | MALDI-TOF | rs25487, rs1799782 | ORR, OS, PFS | 7 |
| Du | 2014 | China | III-IV | 161 (108/53) | 60 | 54.7 | qPCR | rs25487 | ORR | 7 |
| Deng | 2015 | China | IIIB-IV | 97 (66/31) | 57 | 40.2 | Direct sequencing | rs25487 | ORR, PFS | 6 |
| Han | 2015 | China | IIIB-IV | 325 (116/209) | 57.6 | 68.3 | PCR-RFLP | rs25487, rs1799782 | ORR, OS | 7 |
| Liu | 2015 | China | IIIB-IV | 322 (226/96) | 62.5 | 43.5 | PCR-RFLP | rs25487, rs1799782 | ORR, OS | 6 |
| Zhao | 2015 | China | III-IV | 206 (124/82) | 56.1 | 65.5 | PCR-RFLP | rs25487, rs1799782 | ORR, OS | 7 |
| Chen | 2016 | China | III-IV | 1024 (724/300) | NR | 55.6 | MALDI-TOF | rs25487 | ORR | 6 |
| Bu | 2016 | China | III-IV | 141 (100/41) | 55.9 | 66.0 | PCR-RFLP | rs25487, rs1799782 | ORR, OS | 6 |
| Liu | 2016 | China | IIIB-IV | 252 (104/148) | 56.3 | 75.4 | PCR-RFLP | rs25487, rs1799782 | ORR, OS | 7 |
| Liao | 2018 | China | IV | 58 (39/19) | 58 | 44.8 | TaqMan | rs25487 | ORR, OS | 7 |
| Dong | 2018 | China | IIIB-IV | 152 (101/51) | 52 | 52.0 | MALDI-TOF | rs25487 | ORR | 6 |
PCR-RFLP: polymerase chain reaction restriction fragment length polymorphism; PCR-CTTP: PCR with the confronting-two-pair primer; MALDI-TOF: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; NR: not reported. NOS: Newcastle-Ottawa Scale.